Takeda Pharmaceutical Co Ltd (TKPHF) stock
Close on Oct 19, 2026Market cap $134.41BP/E –Yield –
Takeda Pharmaceutical Co Ltd saw revenue fall 1.7% to ¥4.51T over fiscal 2026. Operating income fell 98.2% to ¥6.22B, moving the operating margin from 7.5% to 0.1%. Free cash flow was ¥865.43B, up 1.1% from a year earlier. At the latest close the market valued the company at ¥21.08T.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- ¥21.08T
- P/E ratio
- –
- Price to sales
- 4.68
- Price to book
- 2.84
- Dividend yield
- –
- Free cash flow yield
- 4.10%
Fundamentals
- Revenue
- ¥4.51T
- Net income
- -¥152.39B
- EPS, diluted
- -96.75 JPY
- Free cash flow
- ¥865.43B
Trading
- Previous close
- $38.64
- Open
- $39.00
- Day's range
- $39.00 – $39.00
- Volume
- 1,045
- Average volume (20 days)
- 13,250
- Beta (5 years)
- 0.22
- RSI (14 days)
- 71.9
- Volatility (1 year)
- 21.7%
- Relative volume
- 1.54×
- WACC
- 7.0%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | TKPHF | S&P 500 | Difference | TKPHF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.5% | +0.6% | +3.8 pts | ||
| 3 months | +14.4% | +3.4% | +11.0 pts | ||
| Year to date | +31.1% | +13.3% | +17.8 pts | ||
| 1 year | +39.2% | +16.6% | +22.5 pts | ||
| 3 years | +49.9% | +86.4% | −36.5 pts | +14.4% | +23.1% |
| 5 years | +74.0% | +81.9% | −7.8 pts | +11.7% | +12.7% |
| 10 years | +28.5% | +318.9% | −290.4 pts | +2.5% | +15.4% |
Eleven years at a glance
Fiscal years 2016 to 2026, JPY
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Takeda Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Takeda Pharmaceutical
Pharmaceutical Preparations
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in research, development, and commercialization of prescription therapeutics. The organization centers its commercial operations around six primary areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its diversified product lineup includes key offerings such as Entyvio, Gattex, Takhzyro, Gammagard Liquid, Hyqvia, Adcetris, Vyvanse, and the Qdenga vaccine. Serving patients across the globe suffering from both widespread conditions and rare disorders, the business develops treatments spanning biologics, small molecules, and plasma extractions.
Company profile, executives and historyTakeda Pharmaceutical stock: common questions
What is Takeda Pharmaceutical's stock price?
TKPHF closed at $39.00 on Oct 19, 2026, up 0.93% on the day.
What is Takeda Pharmaceutical's market cap?
Takeda Pharmaceutical was worth $134.41B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is TKPHF's P/E ratio?
Takeda Pharmaceutical lost money over fiscal 2026 (diluted EPS -96.75 JPY), so it has no meaningful P/E ratio.
How much revenue does Takeda Pharmaceutical make?
Takeda Pharmaceutical reported revenue of ¥4.51T for fiscal 2026, down 1.7% from a year earlier.
Does Takeda Pharmaceutical pay a dividend?
No. Takeda Pharmaceutical has not paid a cash dividend over the last twelve months.
How has TKPHF stock performed over the past year?
Including dividends, TKPHF returned +39.2% over the past year, against +16.6% for the S&P 500.
Who are Takeda Pharmaceutical's competitors?
Companies most similar to Takeda Pharmaceutical by business, industry and size include NVO, RDY, AZN, PFE, LLY.